Elicio Therapeutics Inc
Company Profile
Business description
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Contact
451 D Street
Suite 501, 5th Floor
BostonMA02210
USAT: +1 857 209-0050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
33
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.40 | 39.10 | -0.42% |
| CAC 40 | 8,352.00 | 16.91 | -0.20% |
| DAX 40 | 26,598.64 | 151.31 | -0.57% |
| Dow JONES (US) | 51,615.20 | 732.35 | -1.40% |
| FTSE 100 | 10,881.55 | 21.01 | -0.19% |
| HKSE | 23,753.84 | 116.24 | 0.49% |
| NASDAQ | 24,553.04 | 583.23 | -2.32% |
| Nikkei 225 | 59,662.02 | 1,480.33 | -2.42% |
| NZX 50 Index | 14,303.77 | 130.09 | 0.92% |
| S&P 500 | 7,421.52 | 140.15 | -1.85% |
| S&P/ASX 200 | 9,044.70 | 37.50 | -0.41% |
| SSE Composite Index | 3,602.57 | 31.78 | -0.87% |